Clinical Trial Detail

NCT ID NCT02689921
Title NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT)
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Midwestern Regional Medical Center
Indications

Her2-receptor positive breast cancer

Therapies

Anastrozole

Letrozole

Leuprolide

Pertuzumab + Trastuzumab

Exemestane

Age Groups: adult senior

Additional content available in CKB BOOST